Early & Accurate Diagnosis

Due to the complex and varied symptoms related to hATTR amyloidosis, early diagnosis is rare. And misdiagnosis is common.

Equitable Access to Treatment

There is an unjustifiable lack of equity to treatment for hATTR amyloidosis across Europe. Although therapies are approved at a European level, access across individual countries varies.

Guidance On Genetic Testing

There is limited guidance on genetic testing for hATTR amyloidosis. Patients who undergo genetic testing also fear that genetic discrimination may impact their health insurance or life insurance.

Support for Families & Carers

The role and needs of families, partners, and carers who support hATTR patients are not widely recognised.

Broad Access to Guidelines

Guidelines exist for diagnosing and managing hATTR amyloidosis, but publication is confined to medical and academic literature. Disseminating treatment guidelines to advocacy groups can drive greater disease state awareness at a public and policy level.

UNMET NEEDS in hATTR Amyloidosis

EAfPA

LEARN MORE
GAFPA.org